Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive …
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly
differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Read More
Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. Leveraging our expertise in optics, image acquisition, and image analysis, Nikon Instruments is able to offer a wide range of solutions for live cell imaging and quality control in the stem cell and
regenerative medicine industry.
Aiforia Inc. is a software company specialized in developing intelligent, cloud-based image analysis solutions for Neuroscience & digital pathology. Bringing together Deep Learning for tissue-based Image analysis and high-performance Cloud computing. Algorithms are available through professional services or via a self-service model, where users can create their own Deep Learning algorithms using a browser-based interface.
Rho, a contact research organization (CRO) located in Chapel Hill, NC, provides a full range of services across the entire drug development process. For more than 30 years, Rho has been a trusted partner to leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, innovation technologies, and therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.
Bryant University’s Executive Development Center offers professional and business certificates and courses that provide high-level management skills in critical business areas. We work with you and your company to select the best program to meet your educational needs. Courses and certificate programs are designed for emerging leaders, managers and those high potential, career aspiring individuals and growth-focused companies.
Learn and earn a certificate, prepare for certification – your competitive advantage.
Care Clinique is a measurable patient recruitment company that specializes in large-scale marketing campaigns without breaking the bank.
Our combined 25 years’ experience as marketing and healthcare experts enables us to deliver accurate patient demographics timely and efficiently.
Having recruited over 15,000 patients in the last 6 months across 50 states equipped Care Clinique with valuable insights that we utilize to our client’s best advantage.
Proprietary MultiBrain® Technology enables simultaneous sectioning and staining of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across treatment groups. Coupling mass production neurohistologic methods with staining expertise including standard stains, immunohistochemistry and specialty stains for disintegrative degeneration and Alzheimer’s pathology, NSA significantly reduces client’s R&D cycle times.
sRNAlytics is the leader in small RNA biomarker discovery. Their platform combines next-generation-sequencing with data science to discover small RNA biomarkers that diagnose and stratify disease, monitor disease progression and predict drug response. Case studies have proven their effectiveness across neurology and oncology spanning all stages of drug development. Customers include academic and industry research groups, who leverage the technology to optimize clinical trials, measure and predict drug response, and discover new drug targets.